Latest news
25 items- PRTentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEOTentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi
- 13D/GSEC Form SC 13G/A filed by Aptinyx Inc. (Amendment)SC 13G/A - Aptinyx Inc. (0001674365) (Subject)
- SECAptinyx Inc. filed SEC Form 8-K: Other Events8-K - Aptinyx Inc. (0001674365) (Filer)
- SECAptinyx Inc. filed SEC Form 8-K: Other Events8-K - Aptinyx Inc. (0001674365) (Filer)
- SECSEC Form 25-NSE filed by Aptinyx Inc.25-NSE - Aptinyx Inc. (0001674365) (Subject)
- SECAptinyx Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Aptinyx Inc. (0001674365) (Filer)
- 13D/GSEC Form SC 13D/A filed by Aptinyx Inc. (Amendment)SC 13D/A - Aptinyx Inc. (0001674365) (Subject)
- SECSEC Form DEF 14A filed by Aptinyx Inc.DEF 14A - Aptinyx Inc. (0001674365) (Filer)
- SECSEC Form S-8 POS filed by Aptinyx Inc.S-8 POS - Aptinyx Inc. (0001674365) (Filer)
- SECSEC Form RW filed by Aptinyx Inc.RW - Aptinyx Inc. (0001674365) (Filer)
- SECSEC Form S-8 POS filed by Aptinyx Inc.S-8 POS - Aptinyx Inc. (0001674365) (Filer)
- SECSEC Form S-8 POS filed by Aptinyx Inc.S-8 POS - Aptinyx Inc. (0001674365) (Filer)
- SECSEC Form S-8 POS filed by Aptinyx Inc.S-8 POS - Aptinyx Inc. (0001674365) (Filer)
- SECSEC Form PRE 14A filed by Aptinyx Inc.PRE 14A - Aptinyx Inc. (0001674365) (Filer)
- SECSEC Form 10-Q filed by Aptinyx Inc.10-Q - Aptinyx Inc. (0001674365) (Filer)
- SECSEC Form NT 10-Q filed by Aptinyx Inc.NT 10-Q - Aptinyx Inc. (0001674365) (Filer)
- SECAptinyx Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Aptinyx Inc. (0001674365) (Filer)
- NEWS12 Health Care Stocks Moving In Friday's Intraday SessionGainers Nanobiotix (NASDAQ:NBTX) shares rose 238.9% to $6.88 during Friday's regular session. As of 13:30 EST, Nanobiotix's stock is trading at a volume of 34.0 million, which is 1334582.0% of its average full-day volume over the last 100 days. The company's market cap stands at $242.3 million. Owens & Minor (NYSE:OMI) shares moved upwards by 35.71% to $18.39. The current volume of 1.5 million shares is 150.0% of Owens & Minor's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $1.4 billion. The company's, Q1 earnings came out today. ImmunityBio (NASDAQ:IBRX) stock rose 35.14% to $5.23. Trading volume for this se
- NEWSWhy Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day SessionGainers Nanobiotix S.A. (NASDAQ:NBTX) shares jumped 127% to $4.53 after the company announced it is entering into final contract negotiations after agreement to a non-binding term sheet for development and commercialization of NBTXR3 with a major global pharmaceutical company. PacWest Bancorp (NASDAQ:PACW) gained 53% to $4.86. Shares of beaten-down regional banking stocks surged on Friday following a report by Bloomberg that the Federal Deposit Insurance Corporation may exempt smaller banks with assets below $10 billion from contributing to its Deposit Insurance Fund. Minim, Inc. (NASDAQ:MINM) shares climbed 42% to $4.07 after dropping around 19% on Thursday. fuboTV Inc. (NYSE:FUBO)
- SECAptinyx Inc. filed SEC Form 8-K: Other Events, Leadership Update, Financial Statements and Exhibits8-K - Aptinyx Inc. (0001674365) (Filer)
- SECSEC Form 10-K/A filed by Aptinyx Inc. (Amendment)10-K/A - Aptinyx Inc. (0001674365) (Filer)
- SECAptinyx Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - Aptinyx Inc. (0001674365) (Filer)
- SECAptinyx Inc. filed SEC Form 8-K: Leadership Update8-K - Aptinyx Inc. (0001674365) (Filer)
- NEWSStocks That Hit 52-Week Lows On FridayOn Friday, 93 stocks made new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Canopy Gwth (NASDAQ:CGC) was the largest, in terms of market cap, to set a new 52-week low. Biodexa Pharmaceuticals (NASDAQ:BDRX) was the smallest company in terms of market cap to set a new 52-week low. Ensysce Biosciences (NASDAQ:ENSC)'s stock moved significantly downwards, trading down 802.99% to reach a new 52-week low. CXApp (NASDAQ:CXAI)'s stock bounced back the most, actually rising 0.01% after reaching its new 52-week low. On Friday, the following stocks broke to new 52-week lows: Canopy Gwth (NASDAQ:CGC) stock hit a new 52-week low of $1.75. The stock was up 0.32% on the session.
- NEWSAptinyx Evaluates Strategic Alternatives For Its Future After Failed Trials, 60% LayoffsIn March, Aptinyx Inc (NASDAQ:APTX) completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disorder (PTSD). The study was halted in February before its completion to support the company's capital preservation. In the analysis, NYX-783 did not demonstrate sufficient improvement on the study's primary endpoint to support the continued advancement of the development program by Aptinyx. The company is working with Ladenburg Thalmann as its financial advisor to assist in exploring and evaluating "strategic alternatives." In March, Aptinyx reduced its workforce by approximately 60%. Apti
APTX FAQ
7 questionsWhat does Aptinyx Inc. do?
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and...Where does APTX stock trade?
Aptinyx Inc. (APTX) is listed on NASDAQ.What sector and industry is APTX in?
Aptinyx Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aptinyx Inc. go public?
Aptinyx Inc. (APTX) completed its IPO in 2018.What are analysts saying about APTX?
Aptinyx Inc. has had 2 recent analyst actions on file. The most recent action was from William Blair: Mkt Perform on 2022-04-07. Recent price targets cluster around $1000.00.What companies are similar to APTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare APTX side-by-side with any of them on Quantisnow.How can I track APTX on Quantisnow?
Quantisnow aggregates Aptinyx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APTX to receive live email and push alerts on every new disclosure.